While the role of mTOR signaling has not been studied in the TCT model of CD, several studies have demonstrated efficacy for rapamycin and related molecules (rapalogs) in mouse models of colitis, including chronically dextran sodium sulfate (DSS)-treated and IL-10 knockout mice [7, 20, 21], suggesting that mTOR might be a therapeutic target for IBD. This evidence concerns the gene IL10 and inflammatory bowel disease.